Can we advise ovulation induction in patients with SLE?
The prognosis of systemic lupus erythematosus (SLE) has greatly improved during the last two decades, now allowing most patients to have a very long survival including a satisfactory quality of life. Initially considered contraindicated in SLE due to its overwhelming risks, pregnancy is nowadays allowed in a majority of patients, and fair results are usually obtained under appropriate management (1-3). Consequently, patients thought to have infertility ask the question of a possible therapy, i.e. ovulation induction (OI) associated or not with in vitro fertilization (IVF). Considering the importance of estrogens in the pathogenesis of the disease, the use of such procedures raise several questions in SLE. Though data remain to date extremely scarce, the theoretical and practical aspects of OI in SLE will be briefly reviewed here.
Wechsler
B
B
Service de Médecine Interne, Hôpital Pitié-Salpêtrière, Paris, France.
Le Thi Huong
D
D
Vauthier-Brouzes
D
D
Lefebvre
G
G
Gompel
A
A
Piette
J C
JC
D000328:Adult; D015914:Estrogen Replacement Therapy; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000503:physiopathology; D010062:Ovulation Induction / Q000009:adverse effects*; D011247:Pregnancy; D012216:Rheumatic Diseases / Q000188:drug therapy* / Q000503:physiopathology
D007987:Gonadotropin-Releasing Hormone